Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway.

Cancer research communications·2026
Same author

A light in the dark-reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Characterizing mouse platelet heterogeneity across diverse disease models using spectral flow cytometry and high-dimensional analysis.

Research and practice in thrombosis and haemostasis·2026
Same author

Platelet Subpopulations in Health and Disease: Heterogeneity, Clinical Associations, and Therapeutic Targeting.

Cells·2026
Same author

A new mouse model of thrombopoietin deficiency arising from a spontaneous single base pair mutation.

Platelets·2025
Same author

Introduction to a review series on platelet heterogeneity.

Blood·2025

Related Experiment Video

Updated: Jun 25, 2026

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Cancer and thrombosis.

Elisabeth M Battinelli1, Jack Ansell

  • 1Department of Medicine, E113, Boston University School of Medicine, 88 E. Newton Street, Boston, MA 02118, USA. Jack.ansell@bmc.org.

Current Hematology Reports
|September 1, 2005
PubMed
Summary

Cancer patients face a high risk of venous thromboembolic events (VTE). Low-molecular-weight heparins offer safe and effective treatment and prophylaxis for VTE, potentially improving survival in cancer patients.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Background:

  • Venous thromboembolic events (VTE) are a significant risk for cancer patients.
  • Thrombotic events are a major cause of mortality in individuals with cancer.
  • Current guidelines recommend malignancy screening for VTE patients only when clinical suspicion is high.

Purpose of the Study:

  • To review the role of VTE in cancer patients.
  • To discuss the challenges in managing thrombosis in cancer.
  • To evaluate the efficacy and safety of low-molecular-weight heparins (LMWH) in this population.

Main Methods:

  • Literature review of studies on VTE in cancer.
  • Analysis of treatment options for cancer-associated thrombosis.
  • Evaluation of LMWH for VTE treatment and prophylaxis in cancer.

More Related Videos

Modeling the Effects of Hemodynamic Stress on Circulating Tumor Cells using a Syringe and Needle
05:49

Modeling the Effects of Hemodynamic Stress on Circulating Tumor Cells using a Syringe and Needle

Published on: April 27, 2021

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Related Experiment Videos

Last Updated: Jun 25, 2026

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Modeling the Effects of Hemodynamic Stress on Circulating Tumor Cells using a Syringe and Needle
05:49

Modeling the Effects of Hemodynamic Stress on Circulating Tumor Cells using a Syringe and Needle

Published on: April 27, 2021

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Main Results:

  • LMWH demonstrates safety and efficacy for VTE treatment and prophylaxis in cancer patients.
  • LMWH may offer a survival benefit in this patient group.
  • The impact of LMWH on overall cancer outcomes requires further investigation.

Conclusions:

  • Low-molecular-weight heparins are a valuable therapeutic option for venous thromboembolism in cancer patients.
  • Further research is needed to determine if LMWH treatment influences cancer progression or survival.
  • Management of VTE in cancer remains a critical aspect of patient care.